DEPLOYDatabase

Deployment

SAPIEN 3 Transcatheter Heart Valve at Cleveland Clinic

The SAPIEN 3 is a transcatheter aortic heart valve system used for TAVR (transcatheter aortic valve replacement) to treat severe aortic stenosis without open-heart surgery. FDA-approved for low-risk patients since August 2019, and approved for asymptomatic patients in May 2025. Includes SAPIEN 3 Ultra and SAPIEN 3 Ultra RESILIA variants.

SAPIEN 3 Transcatheter Heart Valve by Edwards Lifesciences · Catalog entry · 1 source · not yet field-verified · Surgical robots

Track SAPIEN 3 Transcatheter Heart Valve at Cleveland Clinic

Recent coverage

See all coverage →

Cleveland Clinic TAVR operators began using a novel high deployment technique for SAPIEN 3 valve implantation in April 2017 to reduce conduction abnormalities and pacemaker requirements.

Safety record

No incidents on record for SAPIEN 3 Transcatheter Heart Valve at Cleveland Clinic.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Trust tier
Catalog entry · 1 source · not yet field-verifiedhow tiers work →
Last updated
2026-08-09
Model
SAPIEN 3 Transcatheter Heart Valve
Company
Edwards Lifesciences
Location
Cleveland Clinic
Status
operational
First seen
2017-04-01
ID
186f9558-ba0c-49e0-8f8c-71081c0d4cb0

Timeline

  1. Apr 2017
    First recorded
    SAPIEN 3 Transcatheter Heart Valve first documented operating at Cleveland Clinic.
  2. Aug 2026
    Current status: operational, reviewed
    Latest recorded state. New status transitions append here as the deployment-status recorder produces them.

On the deployment map

Operates worldwide

SAPIEN 3 Transcatheter Heart Valve is deployed globally rather than at a single verified site, so there is no map pin.

Free to use on your site, with a link back to DEPLOY.

SAPIEN 3 Transcatheter Heart Valve operates in Cleveland Clinic. Explore the full verified map:

Sources (1)

  1. https://consultqd.clevelandclinic.org/higher-positioning-of-sapien-3-valve-reduces-conduction-abnormalities-and-pacemaker-requirements
Methodology: Verified · 1 source (no primary) · last reviewed 2026-08-09

Verification posture

Verified

Low confidence

Review state

Stable

Last reviewed 2026-08-09

Maturity + lifecycle

Maturity stage: production

Lifecycle: active

Architectural position

Cohort: surgical

Sources by quality tier

1
unclassified
Unclassified source

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Methodology surface for SAPIEN 3 Transcatheter Heart Valve at Cleveland Clinic.

Common questions

What is the SAPIEN 3 Transcatheter Heart Valve deployment at Cleveland Clinic?
SAPIEN 3 Transcatheter Heart Valve, built by Edwards Lifesciences, is recorded as a deployment at Cleveland Clinic on the DEPLOY registry. Edwards Lifesciences operates the deployment directly.
Who operates SAPIEN 3 Transcatheter Heart Valve at Cleveland Clinic?
Edwards Lifesciences, the manufacturer of SAPIEN 3 Transcatheter Heart Valve, operates this deployment directly. This is a maker-deploys-its-own-product arrangement rather than a customer pilot.
When did the SAPIEN 3 Transcatheter Heart Valve deployment at Cleveland Clinic go live?
The deployment is recorded as starting April 1, 2017 on the DEPLOY registry. Earlier activity may exist but is not yet sourced.
Have there been incidents at the SAPIEN 3 Transcatheter Heart Valve deployment at Cleveland Clinic?
No active incidents affecting this deployment are recorded on the DEPLOY registry. Absence of recorded incidents is not a guarantee no incident occurred; DEPLOY records only sourced incidents and suppresses retracted ones.

Deploy Watch

Track this deployment.

We notify you when status changes against primary-source evidence, contract events surface, or a related incident is filed.

Machine-readable surfaces